hrBMP4

DRUG2 trials

Sponsors

Stemgen

Conditions

GlioblastomaGlioblastoma Multiforme - braintumor

Phase 1

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

CompletedNCT02869243

StemgenGlioblastoma

Start: 2017-07-18End: 2021-06-30Updated: 2024-02-16

Unknown Phase

A Dose Escalation Phase I Study Of hrBMP4 Administrated Via Convection- Enhanced Delivery In Patients With Progressive And/Or Multiple Recurrent Glioblastoma Multiforme.

Active, not recruitingNL-OMON46932

StemgenGlioblastoma Multiforme - braintumor

Start: 2017-07-11Target: 9Updated: 2024-02-28

Related Papers

Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial.

2023-08-1023 citations